Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -3.14% is 61% above its 5-year average of -7.96%, near the low end of its 5-year range (-146.61%–1694.96%).
44.75% above its 12-month average of -5.68%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 10.15%.
NET PROFIT MARGIN
-3.14%
NET PROFIT MARGIN AVG TTM
-5.68%
NET PROFIT MARGIN AVG 3Y
-8.05%
NET PROFIT MARGIN AVG 5Y
-7.96%
NET PROFIT MARGIN AVG 10Y
1.76%
NET PROFIT MARGIN AVG 15Y
11.43%
NET PROFIT MARGIN AVG 20Y
12.42%
CURRENT VS TTM AVG
+44.75%
CURRENT VS 3Y AVG
+61.00%
CURRENT VS 5Y AVG
+60.57%
CURRENT VS 10Y AVG
-278.07%
CURRENT VS 15Y AVG
-127.48%
CURRENT VS 20Y AVG
-125.29%
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Anika Therapeutics, Inc.
Market Cap
$256.35M
Net Profit Margin
-3.14%
TTM Avg
-5.68%
3Y Avg
-8.05%
5Y Avg
-7.96%
Market Cap
$255.32M
Net Profit Margin
-8.78%
TTM Avg
-964.82%
3Y Avg
-2640.79%
5Y Avg
-1760.53%
Market Cap
$254.80M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2265.94%
5Y Avg
-2185.44%
Market Cap
$260.77M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-5482.65%
5Y Avg
-3802.53%
Market Cap
$262.48M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$262.58M
Net Profit Margin
-249.94%
TTM Avg
-1079.05%
3Y Avg
-1080.63%
5Y Avg
-787.30%
Market Cap
$263.68M
Net Profit Margin
-10994.73%
TTM Avg
-520.92%
3Y Avg
-360.66%
5Y Avg
-288.77%
Market Cap
$266.10M
Net Profit Margin
-43.70%
TTM Avg
-35.13%
3Y Avg
-15.36%
5Y Avg
-13.33%
Market Cap
$244.98M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | $256.35M | -3.14% | -5.68% | -8.05% | -7.96% |
| Century Therapeutics, Inc. (IPSC)vs › | $255.32M | -8.78% | -964.82% | -2640.79% | -1760.53% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $254.80M | 0.00% | 0.00% | -2265.94% | -2185.44% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $260.77M | 0.00% | 0.00% | -5482.65% | -3802.53% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $262.48M | 0.00% | 0.00% | 0.00% | 0.00% |
| AC Immune S.A. (ACIU)vs › | $262.58M | -249.94% | -1079.05% | -1080.63% | -787.30% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $263.68M | -10994.73% | -520.92% | -360.66% | -288.77% |
| OraSure Technologies, Inc. (OSUR)vs › | $266.10M | -43.70% | -35.13% | -15.36% | -13.33% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $244.98M | 0.00% | 0.00% | 0.00% | 0.00% |
| Invivyd, Inc. (IVVD)vs › | $244.52M | -183.90% | -383.83% | -191.92% | -127.94% |
Operating Margin
-4.2%
Net Profit Margin
-3.1%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 10.15% |
| 2026-03-31 | -17.07% |
| 2025-12-31 | 0.95% |
| 2025-09-30 | -8.37% |
| 2025-06-30 | -14.07% |
| 2025-03-31 | -18.62% |
| 2024-12-31 | 1694.96% |
| 2024-09-30 | -77.20% |
| 2024-06-30 | -0.29% |
| 2024-03-31 | -11.14% |
| 2023-12-31 | -146.61% |
| 2023-09-30 | -15.86% |
| 2023-06-30 | -6.19% |
| 2023-03-31 | -27.29% |
| 2022-12-31 | -12.39% |
| 2022-09-30 | -10.37% |
| 2022-06-30 | -7.17% |
| 2022-03-31 | -7.99% |
| 2021-12-31 | -16.17% |
| 2021-09-30 | 1.41% |
| 2021-06-30 | 17.12% |
| 2021-03-31 | 8.28% |
| 2020-12-31 | -47.90% |
| 2020-09-30 | -20.23% |
| 2020-06-30 | -25.13% |
| 2020-03-31 | 16.37% |
| 2019-12-31 | 13.61% |
| 2019-09-30 | 30.98% |
| 2019-06-30 | 31.02% |
| 2019-03-31 | 18.23% |
| 2018-12-31 | 28.63% |
| 2018-09-30 | 28.37% |
| 2018-06-30 | 33.03% |
| 2018-03-31 | -31.44% |
| 2017-12-31 | 27.45% |
| 2017-09-30 | 25.33% |
| 2017-06-30 | 33.98% |
| 2017-03-31 | 23.49% |
| 2016-12-31 | 28.15% |
| 2016-09-30 | 34.71% |
| 2016-06-30 | 32.41% |
| 2016-03-31 | 30.94% |
| 2015-12-31 | 35.74% |
| 2015-09-30 | 35.39% |
| 2015-06-30 | 34.14% |
| 2015-03-31 | 22.65% |
| 2014-12-31 | 33.61% |
| 2014-09-30 | 27.98% |
| 2014-06-30 | 35.40% |
| 2014-03-31 | 44.19% |
| 2013-12-31 | 31.31% |
| 2013-09-30 | 27.92% |
| 2013-06-30 | 28.30% |
| 2013-03-31 | 20.12% |
| 2012-12-31 | 19.74% |
| 2012-09-30 | 11.14% |
| 2012-06-30 | 19.04% |
| 2012-03-31 | 13.31% |
| 2011-12-31 | 15.63% |
| 2011-09-30 | 16.13% |
| 2011-06-30 | 14.14% |
| 2011-03-31 | 2.76% |
| 2010-12-31 | 9.18% |
| 2010-09-30 | 8.54% |
| 2010-06-30 | 7.36% |
| 2010-03-31 | 5.73% |
| 2009-12-31 | 6.57% |
| 2009-09-30 | 14.01% |
| 2009-06-30 | 10.04% |
| 2009-03-31 | 5.68% |
| 2008-12-31 | 12.21% |
| 2008-09-30 | 12.00% |
| 2008-06-30 | 8.97% |
| 2008-03-31 | 7.22% |
| 2007-12-31 | 17.38% |
| 2007-09-30 | 22.55% |
| 2007-06-30 | 19.22% |
| 2007-03-31 | 19.56% |
| 2006-12-31 | 17.78% |
| 2006-09-30 | 21.36% |
| 2006-06-30 | 17.34% |
| 2006-03-31 | 12.67% |
| 2005-12-31 | 15.04% |
| 2005-09-30 | 25.16% |
| 2005-06-30 | 19.05% |
| 2005-03-31 | 16.49% |
| 2004-12-31 | 22.92% |
| 2004-09-30 | 13.80% |
| 2004-06-30 | 12.22% |
| 2004-03-31 | 126.79% |
| 2003-12-31 | 15.98% |
| 2003-09-30 | 11.39% |
| 2003-06-30 | -2.44% |
| 2003-03-31 | -9.25% |
| 2002-12-31 | 15.90% |
| 2002-09-30 | -22.82% |
